Related Pages for BIOCON
BIOCON
Biocon Limited.No results found.
BIOCON
357.8
Related News - BIOCON
Biocon: Co. Receives Health Canada Approval For Biosimilars Bosaya And Vevzuo, Expected To Help Over 2 Million Adults With Osteoporosis And Hundreds With Bone Metastases
21 Apr 2026 08:47 AM
Biocon: Co. Receives Health Canada Approval For Biosimilars Bosaya And Vevzuo, Expected To Help Over 2 Million Adults With Osteoporosis And Hundreds With Bone Metastases
Biocon: HSBC on Biocon Buy with Target Price ₹425 as debt reduction and simplified structure create strong growth foundation, with execution of new biosimilar launches, improving profitability and cash flows, and market share gains in biosimilars as key catalysts.
20 Apr 2026 09:03 AM
Biocon: HSBC on Biocon Buy with Target Price ₹425 as debt reduction and simplified structure create strong growth foundation, with execution of new biosimilar launches, improving profitability and cash flows, and market share gains in biosimilars as key catalysts.
Biocon: Company Announces U.S. Launch Of Bosaya™ And Aukelso™ Denosumab Biosimilars
07 Apr 2026 05:23 PM
Biocon: Company Announces U.S. Launch Of Bosaya™ And Aukelso™ Denosumab Biosimilars
Biocon: Company’s Arm Receives FDA Approval For Liraglutide Injection (Gvictoza®) To Treat Type 2 Diabetes, Boosting Its Complex Drug Offerings
12 Mar 2026 09:19 PM
Biocon: Company’s Arm Receives FDA Approval For Liraglutide Injection (Gvictoza®) To Treat Type 2 Diabetes, Boosting Its Complex Drug Offerings
Biocon: FDA Reduces Rules For Drug Companies Making Cheaper Versions Of Expensive Biologic Drugs.
09 Mar 2026 02:47 PM
Biocon: FDA Reduces Rules For Drug Companies Making Cheaper Versions Of Expensive Biologic Drugs.
Biocon: Jefferies on Biocon Hold, Target Price Rs 360
05 Mar 2026 09:04 AM
Biocon: Jefferies on Biocon Hold, Target Price Rs 360
Biocon: Company Invests 315 Crores in Biocon Biosphere and Biocon Pharma Using OCRPS
04 Mar 2026 07:02 AM
Biocon: Company Invests 315 Crores in Biocon Biosphere and Biocon Pharma Using OCRPS
Biocon: Gets U.S. Approval For Weight Loss Drug Liraglutide, With Market Potential Estimated At $127 Million By December 2025
24 Feb 2026 09:11 PM
Biocon: Gets U.S. Approval For Weight Loss Drug Liraglutide, With Market Potential Estimated At $127 Million By December 2025
Jefferies on Biocon Hold, TP Rs 360
16 Feb 2026 09:01 AM
Jefferies on Biocon Hold, TP Rs 360
HSBC maintains buy on Biocon; Cuts target price to ₹445 from ₹455
16 Feb 2026 09:02 AM
HSBC maintains buy on Biocon; Cuts target price to ₹445 from ₹455
Goldman Sachs maintains neutral on Biocon with a target price of ₹375
16 Feb 2026 09:03 AM
Goldman Sachs maintains neutral on Biocon with a target price of ₹375
Biocon: Company Aims For Steady Growth, Better Margins, And Cash Flow-Driven Value Creation, Focusing On Improving Returns. Biocon Expects Increased Growth In Biosimilars Next Fiscal Year, With Current Year Margins Around Mid-20s And Future Margin Improvements Anticipated Without Specific Targets.
16 Feb 2026 08:55 AM
Biocon: Company Aims For Steady Growth, Better Margins, And Cash Flow-Driven Value Creation, Focusing On Improving Returns. Biocon Expects Increased Growth In Biosimilars Next Fiscal Year, With Current Year Margins Around Mid-20s And Future Margin Improvements Anticipated Without Specific Targets.
Biocon: Expects Interest Savings Of Around INR 300 Crores Starting FY27 From Paying Off Structured Debt, With Current Net Debt Between $1.1B And $1.2B And A Debt-EBITDA Ratio Below 2.5X. The CRDMO Division Believes Challenges From A Single Customer Will Be Temporary, Maintaining Confidence In Long-Term Growth.
16 Feb 2026 08:57 AM
Biocon: Expects Interest Savings Of Around INR 300 Crores Starting FY27 From Paying Off Structured Debt, With Current Net Debt Between $1.1B And $1.2B And A Debt-EBITDA Ratio Below 2.5X. The CRDMO Division Believes Challenges From A Single Customer Will Be Temporary, Maintaining Confidence In Long-Term Growth.
Biocon: Company Plans to Launch Semaglutide in India Through Partnerships - Concall Update.
13 Feb 2026 10:16 AM
Biocon: Company Plans to Launch Semaglutide in India Through Partnerships - Concall Update.
BIOCON: Q3 CONS NET PROFIT 1.44B RUPEES VS 251M (YOY); EST 1.69B || Q3 REVENUE 41.7B RUPEES VS 38.2B (YOY)
12 Feb 2026 08:08 PM
BIOCON: Q3 CONS NET PROFIT 1.44B RUPEES VS 251M (YOY); EST 1.69B || Q3 REVENUE 41.7B RUPEES VS 38.2B (YOY)
BIOCON: Q3 EBITDA 8.3B RUPEES VS 770M (YOY) || Q3 EBITDA MARGIN 19.97% VS 19.67% (YOY)
12 Feb 2026 08:09 PM
BIOCON: Q3 EBITDA 8.3B RUPEES VS 770M (YOY) || Q3 EBITDA MARGIN 19.97% VS 19.67% (YOY)
Biocon: Fitch Changes Biocon Biologics Outlook To Positive And Confirms IDR At 'BB-'
06 Feb 2026 12:44 PM
Biocon: Fitch Changes Biocon Biologics Outlook To Positive And Confirms IDR At 'BB-'
Biocon: Company Gets VAI Status From US FDA For Andhra Pradesh Plant After Inspection From November 3 To 7, 2025
28 Jan 2026 06:38 PM
Biocon: Company Gets VAI Status From US FDA For Andhra Pradesh Plant After Inspection From November 3 To 7, 2025
Biocon: Company Achieves 98% Ownership In Biocon Biologics' Equity Shares
21 Jan 2026 08:03 PM
Biocon: Company Achieves 98% Ownership In Biocon Biologics' Equity Shares
Biocon: Co QIP of $460M or Rupees 41.6B || SBI, ICICI Funds Lead
13 Jan 2026 11:38 AM
Biocon: Co QIP of $460M or Rupees 41.6B || SBI, ICICI Funds Lead
